Abstract
Pneumococcal vaccination among the elderly is currently recommended in several western countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of 65+ year olds in the Lazio region (Italy). Baseline net costs per event averted and life-year gained, at 2001 prices, were €34,681 (95%CI: €28,699 to €42,929) and €23,361, respectively (95%CI: €16,419 to €38,297). Lower bacteraemic pneumonia incidence and vaccine effectiveness increased the net cost per life-year gained (ICER) to €53,899 and €74,313, respectively; in the best-case scenario the ICER was €4249. The case definition of invasive pneumococcal disease and, consequently, vaccine effectiveness are major uncertainties in countries with low incidence of pneumonia.
| Original language | English |
|---|---|
| Pages (from-to) | 458-465 |
| Number of pages | 8 |
| Journal | Vaccine |
| Volume | 25 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jan 5 2007 |
Fingerprint
Keywords
- Cost-effectiveness analysis
- Elderly
- Pneumococcal polysaccharide vaccine
ASJC Scopus subject areas
- Immunology
- Microbiology
- Virology
- Infectious Diseases
- Public Health, Environmental and Occupational Health
- veterinary(all)
Cite this
Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy. / Merito, Monica; Giorgi Rossi, Paolo; Mantovani, Jessica; Curtale, Filippo; Borgia, Piero; Guasticchi, Gabriella.
In: Vaccine, Vol. 25, No. 3, 05.01.2007, p. 458-465.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy
AU - Merito, Monica
AU - Giorgi Rossi, Paolo
AU - Mantovani, Jessica
AU - Curtale, Filippo
AU - Borgia, Piero
AU - Guasticchi, Gabriella
PY - 2007/1/5
Y1 - 2007/1/5
N2 - Pneumococcal vaccination among the elderly is currently recommended in several western countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of 65+ year olds in the Lazio region (Italy). Baseline net costs per event averted and life-year gained, at 2001 prices, were €34,681 (95%CI: €28,699 to €42,929) and €23,361, respectively (95%CI: €16,419 to €38,297). Lower bacteraemic pneumonia incidence and vaccine effectiveness increased the net cost per life-year gained (ICER) to €53,899 and €74,313, respectively; in the best-case scenario the ICER was €4249. The case definition of invasive pneumococcal disease and, consequently, vaccine effectiveness are major uncertainties in countries with low incidence of pneumonia.
AB - Pneumococcal vaccination among the elderly is currently recommended in several western countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of 65+ year olds in the Lazio region (Italy). Baseline net costs per event averted and life-year gained, at 2001 prices, were €34,681 (95%CI: €28,699 to €42,929) and €23,361, respectively (95%CI: €16,419 to €38,297). Lower bacteraemic pneumonia incidence and vaccine effectiveness increased the net cost per life-year gained (ICER) to €53,899 and €74,313, respectively; in the best-case scenario the ICER was €4249. The case definition of invasive pneumococcal disease and, consequently, vaccine effectiveness are major uncertainties in countries with low incidence of pneumonia.
KW - Cost-effectiveness analysis
KW - Elderly
KW - Pneumococcal polysaccharide vaccine
UR - http://www.scopus.com/inward/record.url?scp=33845304311&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845304311&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2006.08.005
DO - 10.1016/j.vaccine.2006.08.005
M3 - Article
C2 - 17049685
AN - SCOPUS:33845304311
VL - 25
SP - 458
EP - 465
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 3
ER -